Pioneering the science of time

Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives.

Our company

Photo: K.G., living with systemic mastocytosis

The urgency of now

We are constantly on the move, relentless in our determination to accelerate development of new therapies, expedite clinical trials and quickly bring approved medicines to patients worldwide.

Our pipeline

Photo: D.L., living with non-small cell lung cancer

Precision that moves

We help patients stay one step ahead with therapies that adapt to disease evolution. This includes solving for treatment resistance and intractable sites of progression, as well as pioneering innovative combinations to prolong benefit.

Our platform

Diversity sparks innovation

Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.

Our opportunities

Our commitment to patients

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

read on

Clinical programs

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Avapritinib

development programs

  • Advanced gastrointestinal stromal tumors
  • Advanced systemic mastocytosis
  • Non-advanced systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Pralsetinib

development programs

  • Advanced RET fusion-positive non-small cell lung cancer
  • Advanced RET-altered thyroid cancers
  • Other RET-altered solid tumors
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Blu-263

development program

  • Non-advanced systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

BLU-945, BLU-701 & BLU-451

development programs

  • Advanced EGFR-mutated non-small cell lung cancer
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

BLU-222

Development programs

  • CDK2-vulnerable cancers, including:
    • Hormone receptor-positive, HER2-negative metastatic breast cancer
    • Advanced cyclin E aberrant ovarian, endometrial and other cancers
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Blu-782

development program

Learn more

BLU-782 is an investigational ALK2 inhibitor being developed for the treatment of FOP. In October 2019, we entered into an exclusive, worldwide license agreement with Clementia Pharmaceuticals, a subsidiary of Ipsen, to develop and commercialize BLU-782.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Meet the Blue Crew

Meet the Blue Crew

Pablo Sierra, Associate Medical Director, Iberia & UK, Global Medical Affairs

I am part of the International Medical Affairs Team, responsible for leading the Medical Affairs function on a national level across Spain, Portugal and the UK with a growing team of highly talented people. Our goal is to ensure timely patient access to our transformative medicines by being the bridge between the company and the external scientific/medical community, from early stages of clinical development to commercialization and beyond.

Read on
The Lens

We aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.

read on

Unleashing the potential of kinase therapies

Our presentations at AACR

Seeking to deliver transformative medicines

Download Our latest corporate presentation
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Kate Haviland, Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Kate Haviland, Chief Executive Officer

Dare to be different

We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.

read on